Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial

NCT03982485 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT03982485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03982485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 16, 2018
Completion date
March 29, 2031
Enrollment
196 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer